ZNF800 Knockout cell line (LN-229)

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

ZNF800 (zinc finger protein 800) encodes a zinc finger protein predicted to function as a DNA-binding transcription factor involved in regulation of DNA-templated transcription. It is predicted to act upstream of or within processes related to acinar cell differentiation and endocrine pancreas development. ZNF800 is predicted to localize to the nucleus, although its specific target genes and molecular mechanisms in pancreatic development remain incompletely characterized.

Established in 1979, LN-229 is a widely recognized and standard human glioblastoma cell line. The line was isolated from cells taken from a patient presenting with a malignant right frontal parieto-occipital glioblastoma (PubMed: 10416987). LN-229 cells adhere stably in culture, displaying an epithelial-like morphology, and are extensively utilized to study apoptotic pathways, cellular autophagy, and tumor suppressor gene interactions within neuro-oncology. Consequently, LN-229 serves as a premier and robust in vitro platform utilized globally for investigating glioblastoma multiforme (GBM) progression mechanisms, blood-brain barrier penetrating candidate drug screenings, and the evaluation of targeted therapeutic modalities.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.